Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment
Open Access
- 1 May 2015
- journal article
- Published by Elsevier in Health Policy
- Vol. 119 (5) , 563-568
Abstract
No abstract availableKeywords
Funding Information
- We are grateful to the Editor of the Journal, Wilm Quentin, and two anonymous referees for their constructive comments. We would also like to thank the EUROB for enabling open access for this article. Thanks are also due to Gnosia Achniotou for fruitful d
This publication has 35 references indexed in Scilit:
- General practitioners’ views on polypharmacy and its consequences for patient health careBMC Family Practice, 2013
- Reforms in the Greek pharmaceutical market during the financial crisisHealth Policy, 2013
- The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overviewGenerics and Biosimilars Initiative Journal, 2012
- Pharmaceutical policies in European countries in response to the global financial crisisSouthern Med Review, 2011
- Determinants of branded prescription medicine prices in OECD countriesHealth Economics, Policy and Law, 2011
- Covert pharmaceutical promotion in free medical journalsCanadian Medical Association Journal, 2011
- Reimbursement of pharmaceuticals: reference pricing versus health technology assessmentThe European Journal of Health Economics, 2010
- Responding to the economic crisis: a primer for public health professionalsJournal of Public Health, 2010
- Competition in off-patent drug markets: Issues, regulation and evidenceEconomic Policy, 2008
- The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United StatesPLOS Medicine, 2008